ArticleCurrent microbiology2026
Metabolomic and Docking Insights into Trichoderma viride-Mediated Suppression of Ralstonia solanacearum.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial wilt, caused by Ralstonia solanacearum, is one of the most destructive vascular diseases of tomato (Solanum lycopersicum L.), resulting in severe yield losses and posing major challenges to sustainable crop production. The present study comprehensively provides a novel mechanistic evaluation of the biocontrol potential of Trichoderma viride against R. solanacearum through an integrated framework combining in vitro, in vivo, and in silico approaches. Crude metabolite extracts of T. viride were characterized using GC-HRMS and FTIR to determine their chemical composition and functional groups, while their antagonistic efficacy was assessed through agar well diffusion assays and greenhouse trials. In vitro results revealed notable, concentration-dependent inhibition of R. solanacearum, with maximum inhibition zones of 32.0 ± 1.15 mm at 200 mg/mL, while in vivo treatment significantly reduced disease incidence, delaying symptom expression by three days and lowering the percent disease index (PDI) by 63.3% relative to the untreated control. GC-HRMS profiling identified several bioactive metabolites, notably Methanone (4-nitrophenyl) (4-benzoyl-3-isoxazoyl), an isoxazole derivative exhibiting the strongest molecular docking affinities with key virulence regulators PhcA, PhcR, PehA and RipD (binding energies up to -9.5 kcal mol
Indexed as
Identifiers
42151638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.